J
José Baselga
Researcher at Cornell University
Publications - 29
Citations - 11267
José Baselga is an academic researcher from Cornell University. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 23, co-authored 29 publications receiving 8351 citations. Previous affiliations of José Baselga include Kettering University & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M. Samstein,Chung-Han Lee,Chung-Han Lee,Alexander N. Shoushtari,Alexander N. Shoushtari,Matthew D. Hellmann,Matthew D. Hellmann,Ronglai Shen,Yelena Y. Janjigian,Yelena Y. Janjigian,David Barron,Ahmet Zehir,Emmet Jordan,Antonio Omuro,Thomas Kaley,Sviatoslav M. Kendall,Robert J. Motzer,Robert J. Motzer,A. Ari Hakimi,Martin H. Voss,Martin H. Voss,Paul Russo,Jonathan E. Rosenberg,Jonathan E. Rosenberg,Gopa Iyer,Gopa Iyer,Bernard H. Bochner,Dean F. Bajorin,Dean F. Bajorin,Hikmat Al-Ahmadie,Jamie E. Chaft,Jamie E. Chaft,Charles M. Rudin,Charles M. Rudin,Gregory J. Riely,Gregory J. Riely,Shrujal S. Baxi,Shrujal S. Baxi,Alan L. Ho,Alan L. Ho,Richard J. Wong,David G. Pfister,David G. Pfister,Jedd D. Wolchok,Jedd D. Wolchok,Christopher A. Barker,Philip H. Gutin,Cameron Brennan,Viviane Tabar,Ingo K. Mellinghoff,Lisa M. DeAngelis,Charlotte E. Ariyan,Nancy Y. Lee,William D. Tap,William D. Tap,Mrinal M. Gounder,Mrinal M. Gounder,Sandra P. D'Angelo,Sandra P. D'Angelo,Leonard B. Saltz,Leonard B. Saltz,Zsofia K. Stadler,Zsofia K. Stadler,Howard I. Scher,Howard I. Scher,José Baselga,José Baselga,Pedram Razavi,Pedram Razavi,Christopher A. Klebanoff,Christopher A. Klebanoff,Rona Yaeger,Rona Yaeger,Neil H. Segal,Neil H. Segal,Geoffrey Y. Ku,Geoffrey Y. Ku,Ronald P. DeMatteo,Marc Ladanyi,Naiyer A. Rizvi,Michael F. Berger,Nadeem Riaz,David B. Solit,Timothy A. Chan,Luc G. T. Morris +84 more
TL;DR: Analysis of advanced cancer patients treated with immune-checkpoint inhibitors shows that tumor mutational burden, as assessed by targeted next-generation sequencing, predicts survival after immunotherapy across multiple cancer types.
Journal ArticleDOI
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
Mark D. Pegram,A. Lipton,Daniel F. Hayes,Barbara L. Weber,José Baselga,Debasish Tripathy,Debbie Baly,Sharon A. Baughman,Tom Twaddell,John A. Glaspy,Dennis J. Slamon +10 more
TL;DR: The use of rhuMAb HER2 in combination with CDDP in patients with HER2/neu-overexpressing metastatic breast cancer results in objective clinical response rates higher than those reported previously for CDDP alone, or rhu MAb Her2 alone.
Journal ArticleDOI
A view on drug resistance in cancer
TL;DR: A reductionist approach is taken to define and separate the key determinants of drug resistance, which include tumour burden and growth kinetics; tumour heterogeneity; physical barriers; the immune system and the microenvironment; undruggable cancer drivers; and the many consequences of applying therapeutic pressures.
Journal ArticleDOI
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy,Yang Shen,Helen Won,Bradley Green,Rita A. Sakr,Marie Will,Zhiqiang Li,Kinisha Gala,Sean W. Fanning,Tari A. King,Clifford A. Hudis,Clifford A. Hudis,David Chen,Tetiana Taran,Gabriel N. Hortobagyi,Geoffrey L. Greene,Michael F. Berger,José Baselga,José Baselga,Sarat Chandarlapaty,Sarat Chandarlapaty +20 more
TL;DR: A comprehensive genetic analysis of two independent cohorts of metastatic ER-positive breast tumors and identified mutations in ESR1 affecting the ligand-binding domain (LBD) in 14 of 80 cases that implicate LBD-mutant forms of ER in mediating clinical resistance to hormonal therapy and suggest that more potent ER antagonists may be of substantial therapeutic benefit.
Journal ArticleDOI
The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Maurizio Scaltriti,José Baselga +1 more
TL;DR: Recent advances in understanding in the mechanisms of receptor activation and function, discovery of primary and secondary EGFR somatic mutations, as well as a new generation of anti-EGFR agents provide new leads on the clinical targeting of this receptor.